PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GetCRO

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New B2B Portal for Outsourcing of Pharmaceutical & Biotech R&D Research to Contract Research Organizations Officially Launched - A new B2B portal GetCRO.com, for outsourcing of Pharmaceutical & Biotech R&D research to Contract Research Organizations (CROs), is launched recently. This portal is designed to address challenges faced by Clients & CROs - GetCRO.com
New B2B Portal for Outsourcing of Pharmaceutical & Biotech R&D Research to Contract Research Organizations Officially Launched

 

NewswireToday - /newswire/ - Pune, Maharashtra, India, 2015/08/03 - A new B2B portal GetCRO.com, for outsourcing of Pharmaceutical & Biotech R&D research to Contract Research Organizations (CROs), is launched recently. This portal is designed to address challenges faced by Clients & CROs - GetCRO.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A new outsourcing portal is set to dramatically change the way in which pharmaceutical and biotech companies partner with contract research organisations (CROs). GetCRO.com is designed to streamline the research services marketplace and enable pharma companies to work to tighter budgets by outsourcing contract research.

The launch of GetCRO.com will mean it's easier than ever for pharma and biotech firms to find a CRO with which they can have a long partnership with, resulting in stronger relationships and more effective research. The B2B e-commerce portal allows pharma companies to post their projects and receive bids directly from CROs. Companies can then choose the most suitable CRO for them based on price, experience and credibility.

CROs are set to benefit from GetCRO too; the portal gives them an opportunity to showcase their experience and expertise, and expand their network of business partners and industry contacts.

Demand is currently high in the pharmaceutical and biotech industry for CROs. With drug development costs continuously rising, pharma companies are under pressure to adhere to strict budgets; outsourcing contract research is a highly effective solution. Currently, pharma companies must invest a great deal of time and money in searching for a suitable CRO, which is why GetCRO is a crucial development in the research services marketplace.

GetCRO's global B2B portal matches demand against supply of all services needing to be outsourced in the pharmaceutical industry. In this respect it is hugely beneficial for companies which require immediate research services for urgent projects, or for companies that require research to a capacity which is currently unavailable to them.

Founder of GetCRO.com, Shrikrishna Pawar, has explained why the portal has been created and what it means for the industry: "We have designed this portal based on our decades of experience in this field. We realised that companies and CROs face lots of challenges during the process of outsourcing. This portal aims to address these pain points of pharmaceutical and biotech companies as well as CROs.

"The marketplace is designed in such a way that while maintaining the confidentiality aspects, companies can find and start working with their most suitable CRO partner. This will save a lot of time and costs for the pharma companies looking to outsource. At the same time, CROs can get access to current business opportunities with a significant decrease in their marketing cost."

GetCRO (getcro.com) has a vast database of CROs with expertise in all stages of drug development, including discovery research, generic product development, contract manufacturing, API, clinical research, regulatory affairs and consulting, to name just a few. Each CRO will be provided with a profile - at no cost - which they will maintain with crucial information such as organisation introduction, services offered, infrastructure, achievements and accreditation details.

Pharma companies are able to register and post their projects for free, whilst CROs make pitches for projects also at no cost. CROs only pay fees when they get results and are awarded projects. This is a win-win scenario for both parties; it means that outsourcing contract research is simplified and cost-effective for pharma companies and marketing costs are kept incredibly low for CROs.

To learn more about GetCRO and register as a pharma company or a contract research organisation, visit the website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GetCRO

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New B2B Portal for Outsourcing of Pharmaceutical & Biotech R&D Research to Contract Research Organizations Officially Launched

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Shrikrishna Pawa - GetCRO.com 
+91 97 65159190 support[.]getcro.com / info[.]getcro.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GetCRO securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GetCRO / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)